XenoPort, Inc. (NASDAQ:XNPT) announced today that it will release its first quarter financial results on May 8, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event. XenoPort, Inc. (NASDAQ:XNPT) shares after opening at $3.74 moved to $3.82 on last trade day and at the end of the day closed at $3.61 . Company price to sales ratio in past twelve months was calculated as 27.90 and price to cash ratio as 3.80. XenoPort, Inc. (NASDAQ:XNPT) showed a negative weekly performance of -12.38%.
ArQule, Inc. (NASDAQ:ARQL) announced that it will report its financial results for the first quarter of 2014 on Wednesday, May 7, 2014 at 7:00 a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern Time that day to discuss these results. ArQule, Inc. (NASDAQ:ARQL) shares fell -3.82% in last trading session and ended the day on $1.51. ARQL return on equity ratio is recorded as -36.10% and its return on assets is -22.30%. ArQule, Inc. (NASDAQ:ARQL) yearly performance is -46.64%.
BioTime, Inc. (NYSEMKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that on May 1, 2014, the Company received approximately $6.4 million in equity financing. The funds were raised from current long-term investors in the Company and will be used for funding product development, including this year’s anticipated pivotalRenevia™ clinical trial, as well as other general operating expenses. BioTime, Inc. (NYSEMKT:BTX) shares moved down -9.27% in last trading session and was closed at $2.35 while trading in range of $2.35 – $2.59 – BioTime, Inc. (NYSEMKT:BTX) year to date (YTD) performance is -34.72%.
Genetic Technologies Limited (NASDAQ:GENE) announced it has filed its Quarterly Activities Report for the Quarter ended March 31, 2014 in accordance with the ASX. Total cash receipts from customers during the quarter ended March 31, 2014 were $1.4 million taking the equivalent figure to more than $3.7 million for the nine-month period ended on that date. Genetic Technologies Limited (ADR) (NASDAQ:GENE) weekly performance is -5.88%. On last trading day company shares ended up $1.28. Genetic Technologies Limited (ADR) (NASDAQ:GENE) distance from 50-day simple moving average (SMA50) is -14.59%. Analysts mean target price for the company is $2.50.